To the editor:
Treatment options in chronic myelogenous leukemia
The perspective "Chronic myelogenous leukemia: current treatment options" 1 provides a succinct, direct, and evenhanded approach to a complex topic, for which I congratulate the authors. I have a lone concern with the final aspect of the review, the dependence on age to determine the recommended treatment option. As the authors state, scoring systems devised by Sokal and Hasford can be used to predict survival for individual patients receiving nontransplant therapy. Similarly, Gratwohl's scoring system estimates survival after allotransplantation; the reliability of this scoring system was recently confirmed by the International Bone Marrow Transplant (IBMT) Registry. 2 Advanced age is a poor prognostic factor for all patients, whether they undergo transplantation or receive nontransplant therapies. The other variables used in these scoring techniques are necessary to estimate outcome.
Recipient age may influence outcome in adults undergoing allogeneic transplantation for chronic myelogenous leukemia (CML) to a lesser degree than is commonly thought. Bolwell recently summarized relevant data and concluded that the inclusion of pediatric patients (grouped with young adults) in many studies has led to the impression that older adults fare far more poorly with transplantation than do younger adults. 3 He found only a slightly higher risk of transplantation-related mortality in older compared to younger adults. Data from Seattle 4 and our own center, 5 among others, indicate that conventional allogeneic transplantation can be performed safely in older patients. Data from the same institutions suggest that transplantation less than 6 months 4 and 3 months 5 from diagnosis can further improve results, including in older patients.
Thomas et al's original report of allogeneic transplantation in CML found a direct relationship between mortality rate and interval from diagnosis to transplantation and an association between older age and longer interval from diagnosis to transplantation. 6 Delaying transplantation in older patients contributes to a higher mortality rate. The fact that every study does not demonstrate a significant influence of this interval on outcome does not prove a lack of influence any more than studies that fail to demonstrate an adverse influence of older age prove the absence of an adverse affect. These studies are not appropriately designed to detect the absence of such differences.
Last, results at specific institutions, often with large patient numbers, are clearly better than overall IBMT Registry results. Many studies with favorable results have included large numbers of patients and have utilized similar approaches. Using targeted busulfan and cyclophosphamide, the Seattle group reports one-year transplantation-related mortality rates of approximately 10% and rare relapses. Institutions with poor results should consider referring patients to centers consistently achieving favorable results.
We can all agree that the decision can best be made by a well-informed patient; that patient depends on clinicians to provide an accurate, fair, and complete description of his or her options. 
